Senseonics (SENS)
(Delayed Data from AMEX)
$0.35 USD
+0.02 (7.31%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $0.36 +0.01 (1.69%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.35 USD
+0.02 (7.31%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $0.36 +0.01 (1.69%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Zacks News
Senseonics Stock Down Despite New FDA Approval for Eversense 365
by Zacks Equity Research
SENS' latest regulatory clearance is likely to simplify diabetes management with the help of a long-lasting CGM system.
Sonendo, Inc. (SONX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sonendo (SONX) delivered earnings and revenue surprises of 33.33% and 9.40%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
SOPHiA GENETICS SA (SOPH) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
SOPHiA GENETICS (SOPH) delivered earnings and revenue surprises of 17.86% and 10.05%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Senseonics' (SENS) Deal With Mercy to Drive Eversense CGM Sales
by Zacks Equity Research
Senseonics Holdings (SENS) collaborates with Mercy to bring its Eversense CGM to a healthcare system that is likely to drive its adoption.
Clover Health Investments, Corp. (CLOV) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Clover Health Investments (CLOV) delivered earnings and revenue surprises of 28.57% and 9.75%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Senseonics Holdings (SENS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Senseonics (SENS) delivered earnings and revenue surprises of 25% and 4.99%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Phreesia (PHR) Surges 10.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Phreesia (PHR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Senseonics Holdings (SENS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Senseonics (SENS) delivered earnings and revenue surprises of 0% and 10.01%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
10x Genomics (TXG) delivered earnings and revenue surprises of -35.90% and 5.65%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Senseonics Holdings (SENS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Senseonics (SENS) delivered earnings and revenue surprises of 0% and 35.86%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Sol-Gel Technologies Ltd. (SLGL) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Sol-Gel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of -92.31% and 94.60%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Health Catalyst (HCAT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Health Catalyst (HCAT) delivered earnings and revenue surprises of 50% and 1.16%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Pulmonx Corporation (LUNG) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 7.32% and 11.27%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Computer Programs and Systems (CPSI) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Computer Programs and Systems (CPSI) delivered earnings and revenue surprises of 3.39% and 2.30%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XHE
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
Select Medical (SEM) Plans 3rd Hospital in Central Pennsylvania
by Zacks Equity Research
Select Medical (SEM) joins forces with UPMC to open its third inpatient rehabilitation hospital in Central Pennsylvania to better address the region's post-acute care needs.
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XHE
Encompass Health (EHC) Plans Hospital to Aid Florida Footprint
by Zacks Equity Research
Encompass Health (EHC) unveils plans to fortify its U.S. presence via building a 50-bed inpatient rehabilitation hospital in The Villages, Florida.
Cigna's (CI) Arm Adds Five Digital Health Apps to Its Platform
by Zacks Equity Research
Cigna's (CI) unit bolsters its clinical platform Digital Health Formulary by including five on-line solutions, aiming to relieve people from chronic medical conditions.
Humana (HUM) Brings Home Health Unit of KAH Under CenterWell
by Zacks Equity Research
Humana (HUM) wraps up rebranding KAH's home health operations to the CenterWell brand. This leads to the clubbing of HUM's three payer-agnostic care services into a common suite.
Senseonics Holdings (SENS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Senseonics (SENS) delivered earnings and revenue surprises of 25% and 12.44%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Talkspace, Inc. (TALK) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Talkspace, Inc. (TALK) delivered earnings and revenue surprises of -15.38% and 4.23%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Enovis (ENOV) Q2 Earnings Beat Estimates
by Zacks Equity Research
Enovis (ENOV) delivered earnings and revenue surprises of 20.41% and 1.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Syneos Health (SYNH) Beats Q2 Earnings Estimates
by Zacks Equity Research
Syneos Health (SYNH) delivered earnings and revenue surprises of 4.17% and 1.76%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?